The presence of epidermal growth factor receptor (EGFR) mutations is predictive of a better response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and initial chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC). Here, EGFR is linked to non-small cell lung carcinoma.